Drugs

, Volume 73, Issue 5, pp 463–473 | Cite as

Lorcaserin: A Review of its Use in Chronic Weight Management

Adis Drug Evaluation

Abstract

Oral lorcaserin (BELVIQ®), a selective serotonin 5-HT2C receptor agonist, is indicated in the US as an adjunct to diet and exercise in the chronic weight management of obese adults, or overweight adults with at least one weight-related comorbidity (e.g. dyslipidaemia, hypertension, type 2 diabetes). This article reviews the pharmacological properties, therapeutic efficacy and tolerability of oral lorcaserin in this patient population. In three large randomized, double-blind, multicentre studies, oral lorcaserin was more effective than placebo in the management of obese and overweight adults with or without type 2 diabetes mellitus. Following 12 months’ therapy, significantly higher proportions of lorcaserin than placebo recipients achieved a ≥5 and ≥10 % reduction from baseline in their bodyweight and a significant between-group difference favouring lorcaserin over placebo was observed for the change from baseline in bodyweight. Moreover, among patients who had achieved a ≥5 % reduction in their bodyweight after 12 months’ therapy with lorcaserin, a significantly higher proportion who received lorcaserin for a further 12 months than those who switched to placebo maintained ≥5 % weight loss at 24 months. In general, oral lorcaserin was well tolerated in clinical studies, with hypoglycaemia and headache the most frequently reported adverse events in those with or without type 2 diabetes, respectively. According to a pooled analysis, the risk of US-FDA-defined valvulopathy with lorcaserin is generally low and not statistically significantly different from placebo. From these and other data, the FDA has concluded that lorcaserin is unlikely to elevate the risk of valvulopathy.

References

  1. 1.
    Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease. Expert Rev Cardiovasc Ther. 2010;8(12):1777–801.PubMedCrossRefGoogle Scholar
  2. 2.
    Bays HE. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development. Expert Rev Cardiovasc Ther. 2011;9(3):265–77.PubMedCrossRefGoogle Scholar
  3. 3.
    Halford JCG, Boyland EJ, Lawton CL, et al. Serotonergic anti-obesity agents: past experience and future prospects. Drugs. 2011;71(17):2247–55.PubMedCrossRefGoogle Scholar
  4. 4.
    Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2011;5:1–7.Google Scholar
  5. 5.
    Eisai Inc. BELVIQ (lorcaserin hydrochloride) tablets, for oral use. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf. Accessed 5 Dec 2012.
  6. 6.
    Martin CK, Redman LM, Zhang J, et al. Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2011;96(3):837–45.PubMedCrossRefGoogle Scholar
  7. 7.
    Coleman E. FDA briefing document. 2012. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000SumR.pdf. Accessed 5 Dec 2012.
  8. 8.
    O’Neil P, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–36.CrossRefGoogle Scholar
  9. 9.
    Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–77.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–56.PubMedCrossRefGoogle Scholar
  11. 11.
    Data on file, Eisai Inc., 2013.Google Scholar
  12. 12.
    Fidler MC, Shazer R, Sanchez M, et al. Lorcaserin, a selective 5-HT2C agonist, evaluated as a weight loss agent in obese and overweight patients with type 2 diabetes treated with sulfonylureas or metformin [abstract no. 1908-P]. Diabetes. 2011;60(Suppl. 1):A515.Google Scholar
  13. 13.
    Stubbe S, Zhang J, Sanchez M, et al. Comparative efficacy of lorcaserin for weight loss in high risk obese patients and low risk overweight patients [abstract no. 2882-PO]. Diabetes. 2012;61(Suppl. 1):A713–4.Google Scholar
  14. 14.
    Raether B, Krolikowski J, Sanchez M, et al. Effects of lorcaserin on body composition in the BLOSSOM study of obese and overweight patients [abstract no. 2028-P]. Diabetes. 2012;61(Suppl. 1):A518–9.Google Scholar
  15. 15.
    Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16(7):777–802.PubMedCrossRefGoogle Scholar
  16. 16.
    US Food and Drug Administration. Center for Drug Evaluation and Research. Medical review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022529Orig1s000MedR.pdf. Accessed 30 Jan 2013.
  17. 17.
    Colman E, Golden J, Roberts M, et al. The FDA’s assessment of two drugs for chronic weight management. N Engl J Med. 2012;367(17):1577–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6):897–902.PubMedCrossRefGoogle Scholar
  19. 19.
    Arena Pharmaceuticals Inc. Lorcaserin hydrochloride: briefing document for FDA Advisory Committee meeting. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303200.pdf. Accessed 27 Feb 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations